tbuckley/cabot-search huggingface dataset:
SAT0045 Antibodies Directed against Endogenous and Exogenous Citrullinated Antigens Pre-Date The Onset of Rheumatoid Arthritis
Authors: L. Johansson, F. Pratesi, M. Brink, L. Ärlestig, C. D'Amato, D. Bartaloni, P. Migliorini, S. Rantapää-Dahlqvist
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Anti–citrullinated-peptid/protein antibodies (ACPA) have been detected in individuals pre-dating symptom onset of rheumatoid arthritis (RA), with an initial limited spectrum of reactivities that gradually broadens to different citrullinated substrates typical of RA (1,2). The recent discovery of NETs as source of citrullinated antigens, and namely citrullinated histones H3 and H4 (3). We have previously described deiminated sequences contained in EBV-derived proteins EBNA1 and EBNA2 as specific targets of ACPA in sera from patients with RA (4). <h3>Objectives</h3> The aim was to analyze the evolution of the antibody response predating the symptom onset using citrullinated exogenous (viral peptides) and self (H4 peptides) antigens as substrates to detect ACPA. <h3>Methods</h3> A cohort of 521 individuals sampled before symptoms of RA, and 272 population controls were identified as being donors to the Medical Biobank of Northern Sweden; 241 plasma samples from early RA-patients were also collected. ACPA were detected by ELISA on viral citrullinated peptides derived from Epstein-Barr-virus-encoded protein (EBNA1) and EBNA2 (VCP1 and VCP2) and on histone 4 derived peptides (HCP1 and HCP2). <h3>Results</h3> Anti-VCP1 antibodies were detected in 10.4% of the pre-symptomatic individuals as compared with 36.1% in early RA; anti-VCP2 in 17.1% vs. 52.3%; anti-HCP1 in 10.2% vs. 37.3%; anti-HCP2 in16.3% vs. 48.5%. Anti-VCP and -HCP concentrations were significantly increased in pre-symptomatic individuals as compared with controls (p&lt;0.001) and increased approaching symptom onset. ACPA specific for HCP or VCP appeared simultaneously (median (Q1-Q3) 5.3 (2.9–8.9) years before symptom onset). Combination of anti-VCP1, -VCP2 and–HCP2 and negativity for -HCP1 yielded a high risk ratio (OR=18.70; 95%CI 2.53–138.47; p&lt;0.004). Anti-VCP2 and -HCP2 antibodies were associated in pre-symptomatic individuals with HLA-SE in particular DRB1*0401 but not with the <i>PTPN22</i> T-allele. Three PADI3/PADI4 single nucleotide polymorphisms (rs3003444, rs7542629 and rs11800688) were significantly associated with anti-HCP1 antibodies after Bonferroni corrections. <h3>Conclusions</h3> Anti-VCP and -HCP antibodies predate symptom onset and predict disease development, but no hierarchy of citrullinated epitopes is clear of the ACPA response. These results suggest that no inciting citrullinated antigen so far described is common to all RA patients; rather data suggest a stochastic mechanism in ACPA production. Anti-HCP1 antibodies were associated with PADI polymorphisms. <h3>References</h3> Rantapää-Dahlqvist S, et al. Arthritis Rheum 2003;48:2741–9. Brink M, et al. Arthritis Rheum 2013;65:899–910. Pratesi F, et al. Ann Rheum Dis 2014;73:1414–22. Pratesi F, et al Arthritis Rheum 2006;54:733–41 <h3>Disclosure of Interest</h3> None declared
Outcome of Refractory Anemia with Ringed Sideroblasts Associated with Marked Thrombocytosis (RARS-T) In a Large Cohort of Patients
Authors: Francois Girodon, Julien Broseus, Lourdes Florensa, Esther Zipperer, Susanne Schnittger, Luca Malcovati, Steven Richebourg, Eric Lippert, Jaroslav Cermak, Jyoti Nangalia, Morgane Mounier, Jose Maria Raya, Norbert Gattermann, Torsten Haferlach, Mario Cazzola, Richard Garand, Allou Kaoutar, Marc Maynadie, Carlos Besses, Ulrich Germing, Claudia Haferlach, Erica Travaglino, Sylvie Hermouet
Journal: Blood (2010)
Therapy Related Acute Myelogenous Leukemia and Myelodysplastic Syndrome in Patients with Acute Lymphoblastic Leukemia Treated with the Hyper-CVAD Regimen.
Authors: Dushyant Verma, Deborah Thomas, Susan O’Brien, Stefan Faderl, Charles Koller, Sherry Pierce, Elihu Estey, Guillermo Garcia-Manero, Jorge Cortes, Hagop Kantarjian, Farhad Ravandi
Journal: Blood (2007)
Copper Levels in Patients with Hematological Malignancies
Authors: Zoi Saouli, Michael D. Diamantidis, Athanasios Papadopoulos, Georgia Kaiafa, Fotios I Girtovitis, Zisis Kontoninas, George Ntaios, Charalambos Andreadis, Christos Savopoulos, Apostolos Hatzitolios
Journal: Blood (2008)
AAML0523: A Report From the Children's Oncology Group On the Safety of Clofarabine in Combination with Cytarabine in Pediatric Patients with Relapsed Acute Leukemia.
Authors: Todd Cooper, Todd A. Alonzo, Robert B. Gerbing, John Perentesis, James A. Whitlock, Elizabeth Raetz, William L. Carroll, Alan S. Gamis, B. I. Razzouk
Journal: Blood (2009)
AB0924 Serum Adipokines Levels in Patients with Sarcoidosis
Authors: S. Kobak, M. Akyildiz, A. Gokduman, T. Atabay, H. Vural
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Adipokines are different proteins synthesized by adipose tissue who have an influence on angiogenesis, hemostasis, lipid metabolism and immune system regulation. Sarcoidosis is a chronic inflammatory disease characterized by non-caseating granuloma which etiology is unknown yet. Adipokines may play an important role in the pathogenesis of sarcoidosis. <h3>Objectives</h3> To determine the serum adipokines levels in patients with sarcoidosis and to determine a possible correlation with clinical and laboratory signs of disease. <h3>Methods</h3> Forty-four biopsy proven sarcoidosis patients followed at a single center and age and sex matched 41 healthy volunteers were included in the study. Demographic, clinical, laboratory and radiological data were recorded and body mass index (BMI) was calculated in all patients. Routine laboratory tests (blood glucose, liver and kidney function test) were measured. Serum adiponectin and leptin levels were measured by ELISA method. <h3>Results</h3> Among 44sarcoidosis patients 13 (29.5%) were male and 31 (70.5%) were female. Twenty-one (47.7%) patients had erythema nodosum, three (6.8%) had uveitis, 40 (90.9%) had arthralgia, 23 (52.3%) had ankle arthritis, 15 (34.1%) had enthesitis. Laboratory evaluation showed increased serum ACE level in 24 (54.5%) patients, increased serum calcium level in 11 (25%) patients, increased serum D3 level in 5 (11.4%) patients, increased ESR and CRP levels in 22 (50%) and 23 (52.3%) patients, respectively. Compared with the control group serum adiponectin levels were significantly higher in patients with sarcoidosis (p=0.007). Serum adiponectin level were associated with arthralgia and ankle arthritis (p=0.007, p=0.006 respectively). Serum leptin levels were similar in sarcoidosis patients and controls (p=0.327). There was no relationship between serum leptin level and disease features (p&gt;0.05). <h3>Conclusions</h3> In this study, high serum adiponectin level was detected in patients with sarcoidosis while serum leptin level were similar in the sarcoidosis and control group. Adiponectin, an anti-inflammatory protein may play an important role in the pathogenesis of sarcoidosis. Studies are needed to shed light on this topic. <h3>Disclosure of Interest</h3> None declared
Cord Blood Transplantation from Unrelated Donors for Adults with Advanced Lymphoid Malignancies - A Eurocord-Netcord Group/EBMT-LWP Study.
Authors: Celso A. Rodrigues, Claudio Brunstein, Guillermo Sanz, Marc Renaud, Marcos de Lima, Didier Blaise, Bernard Rio, Adrienne B.M. Madureira, Anna Sureda, John E. Wagner, Eliane Gluckman, Vanderson Rocha
Journal: Blood (2007)
A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)
Authors: Ronald van Vollenhoven, Alexandre Voskuyl, George Bertsias, Cynthia Aranow, Martin Aringer, Laurent Arnaud, Anca Askanase, Petra Balážová, Eloisa Bonfa, Hendrika Bootsma, Dimitrios Boumpas, Ian Bruce, Ricard Cervera, Ann Clarke, Cindy Coney, Nathalie Costedoat-Chalumeau, László Czirják, Ronald Derksen, Andrea Doria, Thomas Dörner, Rebecca Fischer-Betz, Ruth Fritsch-Stork, Caroline Gordon, Winfried Graninger, Noémi Györi, Frédéric Houssiau, David Isenberg, Soren Jacobsen, David Jayne, Annegret Kuhn, Veronique Le Guern, Kirsten Lerstrøm, Roger Levy, Francinne Machado-Ribeiro, Xavier Mariette, Jamil Missaykeh, Eric Morand, Marta Mosca, Murat Inanc, Sandra Navarra, Irmgard Neumann, Marzena Olesinska, Michelle Petri, Anisur Rahman, Ole Petter Rekvig, Jozef Rovensky, Yehuda Shoenfeld, Josef Smolen, Angela Tincani, Murray Urowitz, Bernadette van Leeuw, Carlos Vasconcelos, Anne Voss, Victoria P Werth, Helena Zakharova, Asad Zoma, Matthias Schneider, Michael Ward
Journal: Annals of the Rheumatic Diseases (2016)

Objectives Treat-to-target recommendations have identified ‘remission’ as a target in systemic lupus erythematosus (SLE), but recognise that there is no universally accepted definition for this. Therefore, we initiated a process to achieve consensus on potential definitions for remission in SLE. Methods An international task force of 60 specialists and patient representatives participated in preparatory exercises, a face-to-face meeting and follow-up electronic voting. The level for agreement was set at 90%. Results The task force agreed on eight key statements regarding remission in SLE and three principles to guide the further development of remission definitions: 1. Definitions of remission will be worded as follows: remission in SLE is a durable state characterised by …………………. (reference to symptoms, signs, routine labs). 2. For defining remission, a validated index must be used, for example, clinical systemic lupus erythematosus disease activity index (SLEDAI)=0, British Isles lupus assessment group (BILAG) 2004 D/E only, clinical European consensus lupus outcome measure (ECLAM)=0; with routine laboratory assessments included, and supplemented with physician's global assessment. 3. Distinction is made between remission off and on therapy: remission off therapy requires the patient to be on no other treatment for SLE than maintenance antimalarials; and remission on therapy allows patients to be on stable maintenance antimalarials, low-dose corticosteroids (prednisone ≤5 mg/day), maintenance immunosuppressives and/or maintenance biologics. The task force also agreed that the most appropriate outcomes (dependent variables) for testing the prognostic value (construct validity) of potential remission definitions are: death, damage, flares and measures of health-related quality of life. Conclusions The work of this international task force provides a framework for testing different definitions of remission against long-term outcomes.
AB0847 Non-Specific Chronic Low Back Pain Is Common in Sub-Saharan Africa: A Hospital-Based Study in Cameroon
Authors: F. Kemta Lekpa, M.S. Doualla, M. Singwe-Ngandeu, H. Namme Luma
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Low back pain is the most frequent cause of rheumatic diseases in Africa (1). However the studies are scarce, especially in sub-Saharan Africa. <h3>Objectives</h3> To determine the main characteristics of non-specific chronic low back pain in Cameroon, Central Africa. <h3>Methods</h3> We performed a cross-sectional study in all 6804 patients seen in Rheumatology department in a tertiary healthcare centre, the General Hospital of Douala, Cameroon, between January 2004 and December 2013. All patients followed for low back pain (pain experienced in all the lumbar region of the spine) were screened. Patients were classified into acute low back pain (&lt;3 weeks), subacute low back pain (3 weeks - 3 months) and chronic low back pain (&gt;3 months). Patients with specific low back pain (infection, tumor, fracture, inflammation, …) were excluded from this study. A p&lt;0.05 was considered statistically significant. <h3>Results</h3> During the study period, 3008 patients were seen for low back pain. Of these, 220 patients (7.3%) had specific low back pain and 2788 (92.7%) had non-specific low back pain, including 1302 with chronic low back pain. Chronic low back pain were more common than acute and subacute low back pain (p=0.001) without statistical difference in mean age and sex ratio (p&gt;0.05) (Table 1). Table 2 shows the distribution of patients according to the radiographic lesions found. The disc disease, particularly the degenerative disc disease were the most common radiographic lesions, found in more than half of the patients. <h3>Conclusions</h3> Non-specific chronic low back pain is the most prevalent musculoskeletal condition in Cameroon. It concerns almost half of the patients seen in Rheumatology department. The degenerative disc disease are the most common radiographic lesions. The hospital-based study would explain the marked prevalence of chronic low back pain on acute and subacute low back pain. These latter would probably be more often seen in peripheral hospitals by general practitioners. <h3>References</h3> Louw QA et al. BMC Musculoskelet Disord 2007;8:105. <h3>Disclosure of Interest</h3> None declared
O-016 A prognostic marker for colorectal cancer: combining analyses of ploidy and stroma
Authors: S. Fotheringham, H. Danielsen, T. Hveem, E. Domingo, M. Pradhan, R. Syvertsen, I. Kostolomov, J. Nesheim, E. Johnstone, M. Novelli, I. Tomlinson, R. Kerr, D. Kerr
Journal: Annals of Oncology (2016)
SP0154 Comorbidities of Psoriatic Arthritis and Other Rheumatic Diseases
Authors: D.D. Gladman
Journal: Annals of the Rheumatic Diseases (2016)

Over the past several decades it has become clear that many rheumatologic conditions are complicated by a number of comorbidities. Comorbidities are distinct from extra-articular features of a rheumatologic disorder. These are other conditions that occur in individuals with either inflammatory or non-inflammatory rheumatologic disorders, but are not directly related to the underlying condition. Many rheumatology patients have co-existent diabetes. This is particular true among patients with psoriatic arthritis (PsA). Recent data demonstrate that diabetes occurs with higher prevalence among PsA patients, and its prevalence has increased over the past few decades. Another important comorbidity is cardiovascular disease. Cardiovascular disease occurs more commonly among patients with rheumatoid arthritis, systemic lupus erythematosus, PsA and ankylosing spondylitis, than in the general population. Moreover, cardiovascular events occur at an earlier age in patients with these inflammatory conditions. Hypertension also occurs more frequently among patients with rheumatologic conditions, partly related to the therapy provided. In each of these conditions it seems that the underlying inflammatory condition predisposes to the comorbidity, and in several studies the degree of inflammation is related to both the frequency and severity of the underlying disease. More recently it has become clear that the metabolic syndrome which incorporates obesity, diabetes, hyperlipidemia, and hypertension is increase among patients with PsA, AS and SLE, thus predisposing them to cardiovascular disease. Another comorbidity which affects patients with rheumatologic disorders is depression. This is particularly noticeable among patients with PsA, who also suffer from psoriasis, a condition also known to be associated with depression. The depression may also be related to the inflammatory burden of both skin and joint disease. The management of these comorbidities requires firstly screening for them. Studies have shown that we do not do a good job screening for and treating hypertension, hyperglycemia and hyperlipidemia in rheumatology patients. One issue to consider is who should be doing this, is it the rheumatologist or the family physician, and how it should be done. <h3>Disclosure of Interest</h3> None declared
Concurrent Chemotherapy and Radiation Therapy for Inoperable Locally Advanced Non–Small-Cell Lung Cancer
Authors: Kenneth E. Rosenzweig, Jorge E. Gomez
Journal: Journal of Clinical Oncology (2017)

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice. A 72-year-old man with a 40-pack-year tobacco history developed a cough and decreased exercise tolerance. A chest x-ray demonstrated a right-upper-lobe opacity. Chest computed tomography (CT) scan revealed a 2.5-cm mass in the right upper lobe with multiple mediastinal lymph node disease ( Fig 1 ). A positron emission tomography (PET) scan confirmed the lung lesion and the mediastinal lymphadenopathy without distant metastases. Brain magnetic resonance imaging results were negative. The biopsy specimen revealed adenocarcinoma with no actionable mutations present. Cervical mediastinoscopy was positive for carcinoma in level 2, 3, 4R, and 7 lymph nodes; level 4L was negative. The patient’s stage was T1bN2M0, stage IIIA. His medical history was significant for hyperlipidemia and hypothyroidism. He had smoked one pack a day for 40 years and had quit 15 years earlier. Physical examination was unrevealing, and the patient had an Eastern Cooperative Oncology Group performance status of 0. Because of the extent of lung cancer in the mediastinum, the patient’s cancer was deemed inoperable, and he was referred for consideration of concurrent chemotherapy and radiation.
CBIO-30DISRUPTED OLIGODENDROCYTE PRECURSOR CELL ASYMMETRIC DIVISION GENERATES PHENOTYPES REMINISCENT OF NEOPLASTIC TRANSFORMATION
Authors: Ian Meyers, Hannah Collins, Banafsheh Kadhkodaei, Robin Lerner, Valeri Vasioukhin, Claudia Petritsch
Journal: Neuro-Oncology (2015)

Despite aggressive standard and novel targeted therapies, malignant gliomas recur invariably and develop therapy resistance. Our previous studies have shown that oligodendrocyte progenitor cells (OPCs) undergo asymmetric cell division whereby they generate self-renewing and differentiating cells in a single division by unequally segregating cell fate determinants. We found that premalignant OPC, the origin of glioma in genetically engineered mouse models, exhibit disrupted asymmetric divisions, together with other hallmarks of cancer, including hyper-proliferation (Sugiarto et al., 2011, Cancer Cell 20:328-40). Yet, it is not clear whether disruption of asymmetric division of OPCs is a contributing factor or a consequence of neoplastic transformation. Lethal giant larvae 1 (Lgl1), a gene that was initially identified as a tumor suppressor in Drosophila, has been implicated in the asymmetric localization of cell fate determinants in neural progenitor cells (Klezovitch et al., 2004, Genes Dev 18:559-571). We investigated the effects of Lgl1 depletion on distinct hallmarks of glioma. We find that in murine OPC carrying conditional null alleles of Lgl1, depletion of Lgl1 resulted in reduced rates of asymmetric cell division and other defects previously associated with glioma precursors. Our data suggest that loss of asymmetric divisions contribute to neoplastic transformation. Asymmetric cell divisions of stem and progenitor cells are a point of disruption to which novel therapies can be targeted. Underlying mechanisms for the phenotypes of Lgl1 knockout and their relevance for malignant glioma will be discussed.
Frascati , a Mitochondrial Solute Transporter, and Its Role in Vertebrate Erythropoiesis.
Authors: Barry H. Paw, George C. Shaw, John J. Cope, Kenneth Corson, Candace Hersey, Rebecca Wingert, Gabriele E. Ackermann, David Traver, Nikolaus S. Trede, Bruce A. Barut, Leonard I. Zon
Journal: Blood (2004)
Deferasirox (Exjade®) Treatment of Chelation-Naive and Pre-Chelated MDS Patients with Transfusional Iron-Overload in the Medical Practice:Results From the Observational Studies Extend and Exjange.
Authors: Norbert Gattermann, Oliver Leismann, Rudolf Schlag, Klaus Blumenstengel, Mariele Goebeler, Matthias Groschek, Christoph Losem, Maria Procaccianti, Sieglinde Stern, Alexia Nass, Ulrich Germing
Journal: Blood (2009)
Temsirolimus in Combination with Bendamustine and Rituximab for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Report on An Ongoing Phase I/II Trial
Authors: Georg Hess, Ulrich Keller, Johannes Atta, Christian Buske, Peter Borchmann, Christoph Medler, Mathias Witzens-Harig, Martin H. Dreyling
Journal: Blood (2011)
Chronic Myeloid Leukemia Presenting with Isolated Thrombocythemia: A Case Revealing Its Stem Cell Biology
Authors: Peter Buur van Kooten Niekerk, Anne Stidsholt Roug, Line Nederby, Charlotte Christie Petersen, Hans Beier Ommen, Eigil Kjeldsen, Knud Bendix, Charlotte Guldborg Nyvold, Peter Hokland
Journal: Blood (2012)
Clinical Significance of Serum TARC/CCL17 in ATLL Patients: High TARC/CCL17 Level Is a Significant Unfavorable Prognostic Factor
Authors: Atsushi Inagaki, Takashi Ishida, Hiroki Yano, Fumiko Mori, Asahi Ito, Masaki Ri, Jianmin Ding, Shigeru Kusumoto, Hirokazu Komatsu, Shinsuke Iida, Kentaro Yonekura, Shogo Takeuchi, Yosifusa Takatsuka, Atae Utsunomiya, Ryuzo Ueda
Journal: Blood (2008)
A Recurrent Pattern of Acquired Genomic Abnormalities In Myelodysplasia and Leukemia of Fanconi Anemia Includes Cryptic RUNX1/AML1 abnormalities
Authors: Samuel Quentin, Wendy Cuccuini, Raphael Ceccaldi, Olivier Nibourel, Corinne Pondarre, Marie-Pierre Pages, Nadia Vasquez, Catherine Dubois d'Enghien, Jérome Larghero, Régis Peffault de Latour, Vanderson Rocha, Mauricette Michallet, Jean-Pierre Vannier, Gérard Michel, Eliane Gluckman, André Baruchel, Thierry Leblanc, Dominique Stoppa-Lyonnet, Claude Preudhomme, Gérard Socié, Jean Soulier
Journal: Blood (2010)
Dramatically Enhanced Immunopotency and Anti-Tumor Activity of Liposome-Encapsulated CpG Oligonucleotides (ODN) in Mice Is Paralleled by Vigorous and Broad-Based Immune Responses in Cynomolgus Monkeys after Both Intravenous (IV) and Subcutaneous (SC) Administration.
Authors: Ying K. Tam, Michael J. Hope, Sean C. Semple
Journal: Blood (2006)
Risk Factors For Steroid-Refractory Acute Graft-Versus-Host Disease After Allogeneic Stem Cell Transplantation From Matched Related Or Unrelated Donors
Authors: Claire Calmettes, Stephane Vigouroux, Reza Tabrizi, Arnaud Pigneux, Thibaut Leguay, Krimo Bouabdallah, Marie-Sarah Dilhuydy, Cedric Duclos, Axelle Lascaux, Pierre-Yves Dumas, Sophie Dimicoli-Salazar, Gerald Marit, Noel Milpied
Journal: Blood (2013)
Safety of Intrathecal Liposomal Cytarabine (Depocyte®) Injection Given Prophylactically in Patients with High-Risk Diffuse Large B-Cell Lymphoma: A Report of 22 Patients in Spain.
Authors: Miguel A. Canales, A. Salar, J.A. Diaz, J.J. Ferreiro, S. Ferrer, A. Llorente, D. Caballero, J.A. Garcia-Marco, L. Palomera, J.J. Sanchez-Blanco, E. Gonzalez-Barca
Journal: Blood (2007)
Thrombotic Events in Lupus Anticoagulant Positive Patients Prospectively Correlate with Clinical Risk Factors - the Vienna Lupus Anticoagulant and Thrombosis Study (LATS)
Authors: Florian Posch, Johanna Gebhart, Jacob H. Rand, Bas de Laat, Silvia Koder, Peter Quehenberger, Cihan Ay, Ingrid Pabinger
Journal: Blood (2015)
ERG11 and ABC2 Overexpression but Not ERG11 Gene Mutations Are Involved in the Development of Itraconazole Resistance in Candida Krusei
Authors: Xiaoyuan He, Mingfeng Zhao, Jinyan Chen, Rimao Wu, Jianlei Zhang, Rui Cui, Yanyu Jiang, Jie Chen, Xiaoli Cao, Yi Xing, Juanxia Meng, Qi Deng, Tao Sui
Journal: Blood (2015)
Comparison of Patients (Pts) Characteristic and Treatment Outcomes in Lymphocyte-Predominant (LPHD) and Classical Hodgkin’s Disease (cHD): A Report from the German Hodgkin Lymphoma Study Group (GHSG).
Authors: Lucia Nogova, Thorsten Reineke, Andreas Josting, Karolin Behringer, Beate Pfistner, Volker Diehl, Andreas Engert
Journal: Blood (2004)